한글목차

허셉틴 세계 시장 규모는 2024년에 35억 1,000만 달러로 2030년에는 49억 2,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 5.77%의 CAGR로 성장할 것으로 예상됩니다.

이 시장은 HER2 양성 유방암 및 위암의 발병률 증가에 힘입어 꾸준히 성장하고 있습니다. HER2를 표적으로 하는 치료 전략의 기본 치료제인 허셉틴(성분명: 트라스투주맙)은 HER2를 표적으로 하는 치료 전략의 기본 치료제로 자리매김하고 있습니다. 정밀의학 도입 증가, HER2 진단 검사 개선, 조기 및 전이성 암에 대한 임상 프로토콜에 트라스투주맙이 통합되면서 시장 확대에 기여하고 있습니다. 생존율 향상과 탄탄한 임상적 근거가 지속적으로 수요를 강화하고 있습니다. 진단 도구의 발전, 헬스케어 투자 증가, 치료 편의성을 향상시키는 피하 제제의 보급으로 성장이 더욱 강화될 것입니다. 바이오시밀러 의약품의 확대는 접근성을 높이고, 세계 시장 성장을 뒷받침하는 동시에 경쟁을 심화시키고, 전달 형태와 병용요법의 혁신을 촉진하고 있습니다.

시장 촉진요인

HER2 양성 암의 유병률 증가

주요 시장 과제

특허 만료와 바이오시밀러 경쟁 심화

주요 시장 동향

병용요법과 연속요법으로의 전환

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 허셉틴 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(생물학적 제제, 바이오시밀러)
  • 용도별(유방암, 위암, 기타)
  • 유통 채널별(병원 약국, 전문 약국, 기타)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 허셉틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 허셉틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 허셉틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 허셉틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 허셉틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제14장 경쟁 구도

• Roche Holding AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Amgen Inc.
• Celltrion Healthcare Co., Ltd.
• Biocon Limited
• Mylan N.V.(Viatris)
• Prestige Biopharma
• Shanghai Henlius Biotech, Inc.
• Dr. Reddy's Laboratories

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

영문목차

The global Herceptin market was valued at USD 3.51 billion in 2024 and is projected to reach USD 4.92 billion by 2030, growing at a CAGR of 5.77% over the forecast period. This market is witnessing steady growth driven by the rising incidence of HER2-positive breast and gastric cancers. Herceptin (trastuzumab), a monoclonal antibody, has established itself as a foundational therapy in HER2-targeted treatment strategies. Increasing adoption of precision medicine, improvements in HER2 diagnostic testing, and integration of trastuzumab into clinical protocols for both early and metastatic stages of cancer are supporting market expansion. Enhanced survival outcomes and robust clinical backing continue to strengthen demand. Growth is further reinforced by advancements in diagnostic tools, rising healthcare investments, and the uptake of subcutaneous formulations that improve treatment convenience. The expanding biosimilar landscape is also broadening access, supporting global market growth while intensifying competition and driving innovation in delivery formats and combination therapies.

Key Market Drivers

Increasing Prevalence of HER2-Positive Cancers

The escalating incidence of HER2-positive breast and gastric cancers is significantly boosting demand for Herceptin. HER2 overexpression, identified in a notable subset of patients, enables targeted therapy using trastuzumab. As breast cancer remains the most diagnosed cancer globally, the population eligible for HER2-directed treatments continues to rise. In the U.S., HER2-positive subtypes account for nearly 13.6% of female breast cancer cases, and the burden is similarly high in certain gastric and gastroesophageal cancers, particularly in East Asia and Eastern Europe. The rising need for precise and effective therapies has reinforced Herceptin's clinical value, making it a critical part of standard treatment regimens in oncology.

Key Market Challenges

Patent Expiry and Growing Biosimilar Competition

The expiration of Herceptin's patent protection has opened the market to numerous biosimilars, reshaping competitive dynamics. Regions like the U.S. and Europe have seen an influx of biosimilar alternatives, driving down prices and reducing the market share of the originator product. Healthcare systems, under pressure to optimize costs, are increasingly favoring biosimilars in treatment guidelines and procurement policies. This has intensified pricing pressure and limited brand differentiation. Manufacturers of Herceptin are responding through lifecycle management initiatives, including patient access programs and a strategic pivot toward newer combination therapies. However, sustaining profitability and market share amid widespread biosimilar adoption remains a significant challenge.

Key Market Trends

Shift Toward Combination and Sequential Therapies

The Herceptin market is evolving with a growing emphasis on combination and sequential treatment approaches. Clinicians are increasingly combining trastuzumab with chemotherapies, other biologics, and antibody-drug conjugates to improve outcomes in HER2-positive cancers. The incorporation of pertuzumab and docetaxel alongside trastuzumab, as well as the growing use of antibody-drug conjugates like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan, reflect this shift. These regimens have demonstrated superior efficacy in both metastatic and adjuvant settings. Sequential therapy-transitioning from trastuzumab to ADCs or TKIs-is also being adopted in cases of disease progression, extending Herceptin's role across multiple lines of treatment.

Key Market Players

• Roche Holding AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Amgen Inc.
• Celltrion Healthcare Co., Ltd.
• Biocon Limited
• Mylan N.V. (Viatris)
• Prestige Biopharma
• Shanghai Henlius Biotech, Inc.
• Dr. Reddy's Laboratories

Report Scope:

In this report, the Global Herceptin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herceptin Market, By Product:

• Biologic
• Biosimilar

Herceptin Market, By Application:

• Breast Cancer
• Stomach/Gastric Cancer
• Others

Herceptin Market, By Distribution Channel:

• Hospital Pharmacy
• Specialty Pharmacy
• Others

Herceptin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herceptin Market.

Available Customizations:

Global Herceptin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Herceptin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Biologic, Biosimilar)
  • 5.2.2. By Application (Breast Cancer, Stomach/Gastric Cancer, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Herceptin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Herceptin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Herceptin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Herceptin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Herceptin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Herceptin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Herceptin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Herceptin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Herceptin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Herceptin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Herceptin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Herceptin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Herceptin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Herceptin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Herceptin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Herceptin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America Herceptin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Herceptin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Herceptin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Herceptin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Herceptin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Herceptin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Herceptin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Herceptin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Roche Holding AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Samsung Bioepis Co., Ltd.
• 14.4. Amgen Inc.
• 14.5. Celltrion Healthcare Co., Ltd.
• 14.6. Biocon Limited
• 14.7. Mylan N.V. (Viatris)
• 14.8. Prestige Biopharma
• 14.9. Shanghai Henlius Biotech, Inc.
• 14.10. Dr. Reddy's Laboratories

15. Strategic Recommendations

16. About Us & Disclaimer